ATE373725T1 - Methoden zur feststellung von akute myeloischen leukämie - Google Patents

Methoden zur feststellung von akute myeloischen leukämie

Info

Publication number
ATE373725T1
ATE373725T1 AT02791197T AT02791197T ATE373725T1 AT E373725 T1 ATE373725 T1 AT E373725T1 AT 02791197 T AT02791197 T AT 02791197T AT 02791197 T AT02791197 T AT 02791197T AT E373725 T1 ATE373725 T1 AT E373725T1
Authority
AT
Austria
Prior art keywords
methods
patient
detecting acute
myeloic leukemia
acute myeloic
Prior art date
Application number
AT02791197T
Other languages
English (en)
Inventor
Mitch Raponi
Original Assignee
Ortho Clinical Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Clinical Diagnostics Inc filed Critical Ortho Clinical Diagnostics Inc
Application granted granted Critical
Publication of ATE373725T1 publication Critical patent/ATE373725T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT02791197T 2001-10-30 2002-10-30 Methoden zur feststellung von akute myeloischen leukämie ATE373725T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34101201P 2001-10-30 2001-10-30
US33899701P 2001-10-30 2001-10-30
US34008101P 2001-10-30 2001-10-30
US34093801P 2001-10-30 2001-10-30

Publications (1)

Publication Number Publication Date
ATE373725T1 true ATE373725T1 (de) 2007-10-15

Family

ID=27502594

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02791197T ATE373725T1 (de) 2001-10-30 2002-10-30 Methoden zur feststellung von akute myeloischen leukämie

Country Status (10)

Country Link
US (2) US20040110792A1 (de)
EP (1) EP1478773B1 (de)
JP (1) JP2005522990A (de)
KR (1) KR20040065524A (de)
AT (1) ATE373725T1 (de)
BR (1) BR0206251A (de)
CA (1) CA2451168A1 (de)
DE (1) DE60222590T2 (de)
MX (1) MXPA04004072A (de)
WO (1) WO2003038129A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060194265A1 (en) * 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
EP1361433A3 (de) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Verfahren zur erkennung die therapeutisches Wirkung TNF
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
US7276372B2 (en) 2002-12-20 2007-10-02 Pdl Biopharma, Inc. Antibodies against GPR64 and uses thereof
US20050283854A1 (en) 2003-05-23 2005-12-22 Anton Krumm Recombinant vectors for use in position-independent transgene expression within chromatin
US20050003422A1 (en) * 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
AU2004202980B2 (en) * 2003-07-01 2009-05-07 Veridex, Llc Methods for assessing and treating leukemia
EP1910564A1 (de) * 2005-05-13 2008-04-16 Duke University Genexpressionssignaturen für onkogene wegderegulation
WO2007021807A1 (en) * 2005-08-12 2007-02-22 Schering Corporation Mcp1 fusions
ITRM20050475A1 (it) * 2005-09-19 2007-03-20 Univ Degli Studi Genova Sequenze trascritte da rna polimerasi iii tipo iii e loro uso.
KR20090087491A (ko) * 2006-12-04 2009-08-17 아보트 러보러터리즈 암 치료요법을 위한 동반 진단 검정
CN102317772A (zh) * 2007-03-12 2012-01-11 维里德克斯有限责任公司 测定急性髓性白血病对用法尼基转移酶治疗的反应的方法
MX2009013575A (es) * 2007-06-12 2010-07-02 Schering Corp Biomarcador de histona h2ax (hh2ax) para sensibilidad de inhibidores de farnesil proteina transferasa.
US7932036B1 (en) 2008-03-12 2011-04-26 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
US8211434B2 (en) 2008-11-26 2012-07-03 Allergan, Inc. KLK-13 antibody inhibitor for treating dry eye
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
AU2011282614B2 (en) 2010-07-28 2015-11-26 Janssen Pharmaceutica Nv Methods of determining Acute Myeloid Leukemia response to treatment with farnesyltransferase inhibitors
US11559540B2 (en) 2010-07-28 2023-01-24 Janssen Pharmaceutica Nv Method of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors
US10471055B2 (en) 2015-08-17 2019-11-12 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
HRP20210544T1 (hr) 2016-11-03 2021-08-20 Kura Oncology, Inc. Inhibitori farneziltransferaze za uporabu u liječenju raka

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303301B1 (en) * 1997-01-13 2001-10-16 Affymetrix, Inc. Expression monitoring for gene function identification
US5968784A (en) * 1997-01-15 1999-10-19 Chugai Pharmaceutical Co., Ltd. Method for analyzing quantitative expression of genes
US6203987B1 (en) * 1998-10-27 2001-03-20 Rosetta Inpharmatics, Inc. Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns
EP1254155A4 (de) * 2000-01-26 2003-06-18 Univ Vanderbilt Mob-5/hmob-5 als diagnostisches markierungsmittel
AU2001266587A1 (en) * 2000-05-17 2001-11-26 University Of South Florida Statistical image analysis

Also Published As

Publication number Publication date
BR0206251A (pt) 2004-06-15
US20070048782A1 (en) 2007-03-01
JP2005522990A (ja) 2005-08-04
EP1478773A2 (de) 2004-11-24
US20040110792A1 (en) 2004-06-10
WO2003038129A2 (en) 2003-05-08
CA2451168A1 (en) 2003-05-08
MXPA04004072A (es) 2004-09-06
EP1478773B1 (de) 2007-09-19
DE60222590D1 (de) 2007-10-31
WO2003038129A3 (en) 2004-09-10
DE60222590T2 (de) 2008-06-19
KR20040065524A (ko) 2004-07-22

Similar Documents

Publication Publication Date Title
DE60222590D1 (de) Methoden zur feststellung von akute myeloischen leukämie
WO2004053066A3 (en) Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
ATE403750T1 (de) Methoden und kompositionen zur bewertung von antikörper behandlungen
DE60228592D1 (de) Verfahren zur erkennung von medikamentenempfindlichkeit in patienten mit entzündungskrankheiten
WO2004000094A3 (en) Predictive markers in cancer therapy
NO20052955L (no) Behandling av Huntingtons sykdom med EPA
DE602005021086D1 (de) Pulsoximeter und verfahren zur vermittlung von sauerstoffsättigung und herzfrequenz
NO20062646L (no) System og fremgangsmate for a analysere medisinsk behandlingsdata
NO972475L (no) Ny antitrombotisk formulering, fremgangsmåte for dens fremstilling og anvendelse derav
NO20055832L (no) Fremstilling og anvendelse av arylalkylsyrederivater for behandling av fedme
ATE473781T1 (de) Gerät zum nachweis von arrhythmie in einem medizinprodukt
DE60324925D1 (de) Ace2-aktivierung zur behandlung von herz, lungen, und nierenkrankheit und bluthochdruck
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
ATE461707T1 (de) Pharmazeutische verbindung und methoden zur behandlungen von menschliche karzinome mittels arginin entzug
EP1612281A3 (de) Verfahren zur Beurteilung von Patienten mit akuter myeloischer Leukämie
NO20013301L (no) Ny dialysemetode
DK1397681T3 (da) Fremgangsmåde til identificering af midler til behandling af diabetes
ATE531813T1 (de) System zur überwachung einer bakteriellen tumorbehandlung
BRPI0502433A (pt) métodos para avaliação e tratamento de cáncer
WO2003087315A3 (en) Pre-and post therapy gene expression profiling to identify drug targets
EP1502962A3 (de) Methoden zur Einschätzung und zur Behandlung von Krebserkrankungen
DE60327768D1 (de) Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease
CY1107921T1 (el) Μεθοδος για την προγνωση της αθροιστικης επιβιωσης ασθενων
EP1767656A3 (de) Methoden zur feststellung und behandlung von leukämie
GB0211750D0 (en) Abnormal blood conditions

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties